Overview and Scope
Hyperphosphatemia treatment refers to a class of drugs that boost renal excretion to treat patients’ hyperphosphatemia. The most efficient way to do this is through volume replenishment with saline and forced diuresis with a loop diuretic such as furosemide or bumetanide.
Sizing and Forecast
The hyperphosphatemia treatment market size has grown rapidly in recent years. It will grow from $4.1 billion in 2023 to $4.61 billion in 2024 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to increased incidence of chronic kidney disease (ckd), growth in aging population, high prevalence of diabetes and hypertension, expansion of dialysis patient population, advances in medical research and diagnosis of hyperphosphatemia.
The hyperphosphatemia treatment market size is expected to see rapid growth in the next few years. It will grow to $7.54 billion in 2028 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to rise in lifestyle-related diseases contributing to hyperphosphatemia, continued growth in aging demographics, increasing awareness and diagnosis of hyperphosphatemia, expansion of emerging markets with high disease burden, higher prescription share of calcium-based phosphate binders in emerging countries. Major trends in the forecast period include advancements in hyperphosphatemia treatment technologies, integration of telehealth and remote patient monitoring, collaborations and partnerships for research and development, focus on patient education and lifestyle management in hyperphosphatemia, development of novel phosphate binders and therapies.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/hyperphosphatemia-treatment-global-market-report
Segmentation & Regional Insights
The hyperphosphatemia treatment market covered in this report is segmented –
1) By Product: Sevelamer, Calcium-Based Phosphate Binders, Iron-Based Phosphate Binders, Lanthanum Carbonate, Other products
2) By Distribution channel: Hospital Pharmacy, Retail Pharmacy, Online stores
North America was the largest region in the hyperphosphatemia treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hyperphosphatemia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=5852&type=smp
Major Driver Impacting Market Growth
The increase chronic diseases among patients is driving the growth of the hyperphosphatemia treatment market. Chronic diseases are non-communicable and require long-term care. A vast majority of chronic diseases can be categorized as cardiovascular diseases, chronic kidney disease, chronic respiratory conditions, hyperparathyroidism, diabetes, and cancer. For instance, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million deaths, which is 74% of those caused by non-communicable diseases (NCDs) or chronic diseases every year globally. Furthermore, in February 2023, according to SingleCare Services LLC, a US-based healthcare savings platform, the prevalence of kidney diseases is increasing and each year untreated kidney failure claims the lives of approximately 1 million individuals. There has been an increase in hyperphosphatemia among patients with end-stage renal disease (ESRD), thus contributing to an increase in demand for hyperphosphatemia treatment or drugs .
Key Industry Players
Major companies operating in the hyperphosphatemia treatment market report are Sanofi SA, Akebia Therapeutics Inc., AMAG Pharmaceuticals Inc., Ardelyx Inc., Astellas Pharma Inc., Fresenius Medical Care AG & Co. KGaA, Keryx Biopharmaceuticals Inc., Lupin Limited, Shire plc, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Ultragenyx Pharmaceutical Inc., Unicycive Therapeutics Inc., Vifor Pharma Management Ltd., Zeria Pharmaceutical Co. Ltd., Abbott Laboratories, Amgen Inc., AstraZeneca plc, B. Braun Melsungen AG, Baxter International Inc., Beckman Coulter Inc., Cleveland Clinic, DaVita Inc., Encompass Health Corporation, FMC Corporation, Hospital Corporation of America Healthcare Inc., Kyowa Kirin Pharmaceuticals Co. Ltd., Mayo Clinic, Medtronic plc, OPKO Health Inc., Roche Diagnostics Corporation, Siemens Healthineers AG, Sysmex Corporation, Tenet Healthcare Corporation, Thermo Fisher Scientific Inc., UnitedHealth Group Inc.
The hyperphosphatemia treatment market report table of contents includes:
1. Executive Summary
2. Hyperphosphatemia Treatment Market Characteristics
3. Hyperphosphatemia Treatment Market Trends And Strategies
4. Hyperphosphatemia Treatment Market – Macro Economic Scenario
5. Global Hyperphosphatemia Treatment Market Size and Growth
.
.
.
31. Global Hyperphosphatemia Treatment Market Competitive Benchmarking
32. Global Hyperphosphatemia Treatment Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Hyperphosphatemia Treatment Market
34. Hyperphosphatemia Treatment Market Future Outlook and Potential Analysis
35. Appendix
Top Major Players:
Sanofi SA
Akebia Therapeutics Inc.
Ardelyx Inc
Astellas Pharma Inc
Fresenius Medical Care AG & Co. KGaA
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
